{"entity":{"id":"nct07047001","kind":"trial","name":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma","aka":[],"tldr":"A phase 2 trial of Vorolanib in Renal cell carcinoma, run by Dong Wen, active and no longer recruiting.","summary":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma is a phase 2 interventional study registered as NCT07047001 by Dong Wen, with 60 participants planned, started 2025-04-24 and due to reach its primary completion in 2029-06-30. Interventions recorded: Vorolanib Tablets, Vorolanib + Toripalimab. Conditions recorded: Renal Cell Carcinoma (RCC), Adjuvant.\n\nLinked to the drug Vorolanib because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07047001","url":"https://clinicaltrials.gov/study/NCT07047001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["vorolanib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07047001","phase":"2","setting":"The Efficacy and Safety of Vorolanib Monotherapy or in Combination With Toripalimab for Postoperative Adjuvant Treatment of Renal Cell Carcinoma Patients With Intermediate-high Risk Recurrence Factors: A Multicenter, Randomized, Double-arm, Phase II Exploratory Study","sponsor":"Dong Wen","participation":[{"nct":"NCT07047001","source":"https://clinicaltrials.gov/study/NCT07047001","fetchedAt":"2026-10-07T16:55:22.250Z","studySha256":"7e3fdec05fa85857857f54ce34daeba68694dd30daf0aa171b54415ac439b335","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-07-09","leadSponsor":"Dong Wen","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":60,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2025-04-24","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07047001/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"vorolanib","kind":"drug","name":"Vorolanib","route":"/drugs/vorolanib/"}]}}